Tag Archives: ANEB

Anebulo Pharmaceuticals (ANEB), mcap=$68, price $2.92 vs $3.00

Pharma company in phase 2 clinical trials for an innovative cannabis intoxication treatment – no alternatives for it currently and presents a huge market opportunity worth hundreds of millions or even billions.
ANEB’s drug has already been validated by several studies and excellent Phase II topline results.
Hopes to file IND with FDA by the year-end.
Large and growing target market with increasing legalization/consumption of cannabis.
90% are owned by insiders.
The existing cash balance of $16m is likely to prove inadequate to reach FDA approval, i.e. expected dilution.